Join
Live feed
·
INSIDERFilingvia Quantisnow
Processa Pharmaceuticals Inc. logo

Pres. Research & Development Young David bought $99,289 worth of shares (124,500 units at $0.80), increasing direct ownership by 154% to 205,405 units (SEC Form 4)

ByQuantisnow·Wall Street's wire, on your screen.
PCSA· Processa Pharmaceuticals Inc.
Health Care
Original source

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track PCSA (Processa Pharmaceuticals Inc.) and more on Quantisnow.